LDL-C: lower is better for longer—even at low risk
Abstract Background Low-density lipoprotein cholesterol (LDL-C) causes atherosclerotic disease, as demonstrated in experimental and epidemiological cohorts, randomised controlled trials, and Mendelian randomisation studies. Main text There is considerable inconsistency between existing guidelines as...
Main Authors: | Peter E. Penson, Matteo Pirro, Maciej Banach |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-10-01
|
Series: | BMC Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12916-020-01792-7 |
Similar Items
-
The efficacy and safety of statin in combination with ezetimibe compared with double-dose statin in patients with high cardiovascular risk: A meta-analysis
by: Yunyun Zhu, et al.
Published: (2019-10-01) -
Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes
by: Mario Luca Morieri, et al.
Published: (2021-07-01) -
Cardiovascular risk and dyslipidemia among persons living with HIV: a review
by: Paolo Maggi, et al.
Published: (2017-08-01) -
Physicians' misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes
by: Avogardo, A., et al.
Published: (2022) -
Differences in synthesis and absorption of cholesterol of two effective lipid-lowering therapies
by: S.H. Kasmas, et al.
Published: (2012-11-01)